Donanemab Chemical Properties

form 

Liquid

color 

Colorless to light yellow

Donanemab Usage And Synthesis

History

Donanemab, developed by Eli Lilly and Company, is a monoclonal antibody used for the treatment of Alzheimer's disease. In July 2024, the U.S. Food and Drug Administration (FDA) has effectively approved the Kisunla (donanemab-azbt) injection for the treatment of AD in patients with mild cognitive impairment or mild dementia, in which the drugs were tested in clinical trials. Kisunla is given intravenously, and the recommended dose is given every 4 weeks.

Uses

Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody directed at an N-terminal pyroglutamate amyloid beta (Aβ) epitope. Donanemab has the potential for early Alzheimer's disease research[1][2].

References

[1] Stephen Loucian Lowe, et al. Donanemab (LY3002813) dose-escalation study in Alzheimer's disease. Alzheimers Dement (N Y). 2021 Feb 14;7(1):e12112. DOI:10.1002/trc2.12112
[2] Mark A Mintun, et al. Donanemab in Early Alzheimer's Disease. N Engl J Med. 2021 May 6;384(18):1691-1704. DOI:10.1056/NEJMoa2100708

Donanemab(1931944-80-7)Related Product Information

• Zagotenemab
• Solanezumab
• Satralizumab
• Frovocimab
• Fremanezumab
• Narsoplimab
• Onvatilimab
• Brazikumab
• Nurulimab
• Certolizumab